Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

697
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
697
Disorders of Hemostasis01:24

Disorders of Hemostasis

906
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
906
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

7.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.6K
Coagulation01:09

Coagulation

6.6K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.6K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

5.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K
Introduction to Hemostasis01:05

Introduction to Hemostasis

7.7K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multiomics approach reveals novel regulators of plasma factor V levels, highlighting CLEC4M as a clearance receptor.

Blood·2025
Same author

Thrombophilic thrombomodulin variants.

Blood·2025
Same author

The Change in Liver Volume After Inferior Vena Cava and/or Hepatic Vein Venoplasty in Patients With Budd Chiari Syndrome With at Least One Patent Hepatic Vein Presenting With Ascites.

Journal of clinical and experimental hepatology·2025
Same author

Case Report: Laboratory detection of a thrombotic tendency in a family with hypodysfibrinogenemia and a novel <i>FGG</i> mutation.

Frontiers in cardiovascular medicine·2024
Same author

Plasma levels of complement components C5 and C9 are associated with thrombin generation.

Journal of thrombosis and haemostasis : JTH·2024
Same author

In vitro and ex vivo rescue of a nonsense mutation responsible for severe coagulation factor V deficiency.

Journal of thrombosis and haemostasis : JTH·2023

Related Experiment Video

Updated: Jul 2, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.0K

Factor V variants in bleeding and thrombosis.

Adarsh K Mohapatra1, Alice M Todaro1, Elisabetta Castoldi1

  • 1Department of Biochemistry, CARIM, Maastricht University, Maastricht, the Netherlands.

Research and Practice in Thrombosis and Haemostasis
|February 26, 2024
PubMed
Summary
This summary is machine-generated.

Factor V (FV) variants impact hemostatic balance, influencing bleeding and thrombosis risk. Mutations in the F5 gene can alter FV

Keywords:
FV-shortbleedingfactor Vmutationvenous thrombosis

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.2K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

13.8K

Related Experiment Videos

Last Updated: Jul 2, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.0K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.2K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

13.8K

Area of Science:

  • Hematology
  • Molecular Biology
  • Genetics

Background:

  • Blood coagulation is a complex cascade involving enzymatic reactions.
  • Factor V (FV) is crucial, acting as both a procoagulant and anticoagulant cofactor.
  • Imbalances in FV function are linked to bleeding disorders and venous thrombosis.

Purpose of the Study:

  • To review the procoagulant and anticoagulant roles of Factor V.
  • To explore how F5 gene mutations affect hemostatic balance.
  • To discuss pathological conditions related to FV dysfunction.

Main Methods:

  • Review of scientific literature on Factor V.
  • Analysis of F5 gene mutations and their functional consequences.
  • Discussion of pathological conditions including FV deficiency, APC resistance, and FV-short.

Main Results:

  • Factor V exhibits dual roles in coagulation, essential for thrombin generation and coagulation regulation.
  • F5 gene mutations can disrupt the procoagulant/anticoagulant balance, leading to bleeding or thrombosis.
  • FV deficiency, APC resistance, and FV-short overexpression are key pathological states.

Conclusions:

  • Factor V is a central regulator of hemostasis.
  • Understanding F5 gene variants is critical for diagnosing and managing bleeding and thrombotic disorders.
  • Emerging roles of FV isoforms, like FV-short, require further investigation.